ESC Congress 2024: Powerful Medical Unveils Novel AI Cardiology Research on the Global Stage
Our experience at ESC Congress 2024 in London, organized by the European Society of Cardiology, was nothing short of remarkable. The PMcardio booth buzzed with excitement as we showcased our AI technology to the global community.
Our experience at ESC Congress 2024 in London, organized by the European Society of Cardiology, was nothing short of remarkable. The PMcardio booth buzzed with excitement as we showcased our cutting-edge AI technology to the global cardiology community, eager to explore the future of cardiac care.
PMcardio Booth Highlights and Industry Engagement
At our booth in the digital health area, we were thrilled by the high traffic and the enthusiasm around AI-powered diagnostics. The conversations were dynamic and insightful, reflecting a growing interest in the real-world implementation of AI in hospital settings. We were honored to have ECG experts Dr. Stephen Smith and Dr. Pendell Meyers with us at the PMcardio booth.
Their presence highlighted our strong collaboration with these world-class experts, for which we are deeply grateful. We were thrilled to connect in person with clinical teams from institutions we are already actively collaborating with, strengthening our existing partnerships. Additionally, we forged new relationships within the cardiology community, paving the way for exciting future collaborations.
Dr. Robert Herman’s Presentation: Revolutionizing Acute Coronary Occlusion Detection
A highlight for Powerful Medical at ESC Congress 2024 was Dr. Robert Herman’s presentation on the Digital Health Stage. His talk, titled “International Evaluation of an AI-Powered ECG Model Detecting Acute Coronary Occlusion in Myocardial Infarction,” was featured in the “Top Publications in the European Heart Journal – Digital Health” session.
A highlight of the program at the Digital Health Stage was the presentation by our Chief Medical Officer, Dr. Robert Herman, titled “International Evaluation of an AI-Powered ECG Model Detecting Acute Coronary Occlusion in Myocardial Infarction”. Featured as part of the “Top Publications in the European Heart Journal – Digital Health” session, this talk was an excellent opportunity to demonstrate how our AI technology advances the detection of acute myocardial infarction beyond traditional diagnostic criteria.
International evaluation of an AI-powered ECG model detecting acute coronary occlusion in MI | ESC
This presentation underscored our successful clinical research collaboration with Cardiovascular Center Aalst, aimed at improving the timely detection of heart attacks right at the first point of patient contact and augmenting the chest pain patient pathway with artificial intelligence. The diagnostic performance of the PMcardio AI model, published in the European Heart Journal – Digital Health,demonstrated outstanding performance with an AUC of 0.938, an accuracy of 90.9%, sensitivity of 80.6%, and specificity of 93.7%.
These results surpass the traditional STEMI criteria and closely match the expertise of seasoned ECG professionals. Already in use in clinical practice, this AI model is enhancing the rapid and accurate detection of acute coronary occlusions, leading to better patient outcomes and more efficient patient triage.
Dr. Anthony Demolder’s Presentation: Addressing the Heart Failure Crisis
Another key highlight of the program was Dr. Anthony Demolder’s presentation on our groundbreaking research titled “A smartphone-based AI model to detect left ventricular systolic dysfunction on 12-lead ECG.” This study was presented during the “Advances In Science” session on the Digital Health Stage.
A smartphone-based AI model to detect left ventricular systolic dysfunction on ECG | ESC London 2024
Dr. Demolder emphasized the pressing issue of heart failure, which affects millions worldwide and imposes a massive economic burden on healthcare systems. Our PMcardio AI model, capable of detecting reduced left ventricular ejection fraction (LVEF) with an AUC >0.95 and a sensitivity of 90%, offers a revolutionary approach to early detection. This could dramatically reduce mortality rates and ease financial strains by cutting down on hospitalizations and enabling timely interventions.
Looking Ahead to ESC Congress 2025
We extend our heartfelt thanks to everyone who visited us at our booth in London. The energy and enthusiasm at the ESC Congress 2024 have invigorated us, and we are more committed than ever to advancing the field of cardiology through innovative AI solutions. We’re already looking forward to the next ESC Congress in 2025 in Madrid, where we plan to share even more groundbreaking advancements. See you there!
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
